Clinical trial
Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer
NCT00006101 · Thomas E. Ahlering, Other · Completed
Key facts
| NCT number | NCT00006101 |
|---|---|
| Title | Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer |
| Official title | Randomized Placebo-Controlled, Double-Blind Phase IIb Chemoprevention Trial of Difluoromethylornithine in Brothers and First Cousin Males of Familial Prostate Cancer Probands |
| Lead sponsor | Thomas E. Ahlering, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | eflornithine, Placebo |
| Enrollment | 76 |
| Start date | Oct 1, 1998 |
| Primary completion | Dec 1, 2012 |
| Completion | Dec 1, 2012 |
| First posted | Jan 27, 2003 |
| Last update posted | May 14, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: